Background: Homocysteine is an intermediate sulfur amino acid of methionine metabolism. Hyperhomocysteinemia, characterized by increased level of homocysteine, is an independent and modifiable vascular risk factor which metabolic pathway involves vitamins B6, folate and vitamin B12. Objective: We compared the prevalence of MTHFRC677T polymorphism, homocysteine folate and vitamin B12 in ischemic stroke patient’s subgroups. Methods: We conducted a cross-sectional analytical study. The study included 128 consecutive ischemic stroke patients associated with hyperhomocysteinemia. The MTHFRC677T polymorphism was investigated by TaqMan probes (thermos Fisher Scientific) combined with polymerase chain reaction (PCR). We compared the prevalence of MTHFRC677T polymorphism and homocysteine level in ischemic stroke patient’s subgroups. We adjusted the variable homocysteine level to the covariates, MTHFR polymorphism, folate and vitamin B12 with ANCOVA. Results: The sex ratio (men/women) was 1.5 with an average age of 60 years. The prevalence of MTHFRC677T polymorphism was 19.5% with 18% CT and 1.5% TT. Homocysteine level was 29.89 µmol/l in wildtype patients, 26.54 µmol/l in patients with CT genotype, and 56.17 µmol/l in patients with TT genotype (t=2.04, p=0.033, CI 95% [0.017; 0.407]). The MTHFR polymorphism prevalence, homocysteine, folate and vitamin B12 level did not differ between large brain infarction and multiple small brain infarction patients respectively (chi square: Qobs=0.05, p=0.94, 95% CI; ttest: t=0.716, df=126, p=0.475, 95% CI). Conclusion: The MTHFRT677T genotype increases homocysteine level. MTHFR polymorphism and homocysteine did not influence the subtypes of brain ischemic stroke.
| Published in | Clinical Neurology and Neuroscience (Volume 5, Issue 3) |
| DOI | 10.11648/j.cnn.20210503.14 |
| Page(s) | 55-59 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
MTHFRC677T Polymorphism, Homocysteine, Ischemic Stroke
| [1] | Mazdeh M, Khazaie M, Omrani et al. Association between methylene tetrahydrofolate reductase polymorphisms and risk of ischemic stroke. Int J Neurosci. 2021. 131 (1): 44-48. doi: 10.1080/00207454.2020.1733554. |
| [2] | Wang YH, Yan QH, Xu JY, Li XJ, Cheng MN. High Prevalence and Factors Contributing to Hyperhomocysteinemia, Folate Deficiency, and Vitamin B12 Deficiency among Healthy Adults in Shanghai, China. Biomed Environ Sci; 2019; 32 (1): 63-67. doi: 10.3967/bes2019.010. |
| [3] | Xiang T, Xiang H, Yan M et al. Systemic risk factors correlated with hyperhomocysteinemia for specific MTHFR C677T genotypes and sex in the Chinese population. Ann Transl Med. 2020; 8 (21): 1455. doi: 10.21037/atm-20-6587. |
| [4] | Amouzou EK., et al. “High prevalence of hyperhomocyteinemia arelated to folate deficiency and the 677C→T mutation of the gene encoding methylenetetrahydrofolate reductase in coastal West Africa”. The American Journal of Clinical Nutrition 79.4 (2004): 619-624. |
| [5] | Kombate D, Assogba K, Apetse K, Balogou A. A. K, Amouzou Kousanta E, Grunitzky E. K. Hyperhomocystéinémie chez des victimes d’ischémie cérébrale au CHU de Lomé. Ann Biol Clin 2010; 68: 669-73. |
| [6] | Larsson, S. C.; Traylor, M.; Markus, H. S. Homocysteine and small vessel stroke: A mendelian randomization analysis. Ann. Neurol. 2019, 85, 495–501. |
| [7] | Chen S, Honda T, Ohara T et al. Serum homocysteine and risk of dementia in Japan. J Neurol Neurosurg Psychiatry. 2020 May; 91 (5): 540-546. doi: 10.1136/jnnp-2019-322366. |
| [8] | Chang, G., Kuai, Z., Wang, J. et al. The association of MTHFR C677T variant with increased risk of ischemic stroke in the elderly population: a meta-analysis of observational studies. BMC Geriatr 19, 331 (2019). https://doi.org/10.1186/s12877-019-1304-y. |
| [9] | Yahn GB, Abato JE, Jadavi NM, Role of vitamin B12 deficiency in ischemic stroke risk and outcome. Neural Regen Res 2021: 16: 470–4. |
| [10] | Jadavji NM, Emmerson JT, Shanmugalingam U, MacFarlane AJ, Willmore WG, Smith PD. A genetic deficiency in folic acid metabolism impairs recovery after ischemic stroke. Exp Neurol. 2018. 309: 14-22. |
| [11] | Qin X, Spence JD, Li J et al. Interaction of serum vitamin B12 and folate with MTHFR genotypes on risk of ischemic stroke. Neurology 2020, 94: e1126-1136. |
| [12] | Wang B, Wu H, Li Y et al. Effect of long-term low-dose folic acid supplementation on degree of total homocysteine-lowering: major effect modifiers. Br J Nutr. 2018; 120 (10): 1122-1130. doi: 10.1017/S0007114518002477. |
| [13] | Chita D. S., Tudor A., Christodorescu R. et al. MTHFR gene polymorphisms prevalence and cardiovascular risk factors involved in cardioembolic stroke type and severity. Brain Sci. 2020; 10: 476. doi: 10.3390/brainsci10080476. |
| [14] | Wolffenbuttel, B. H. R., Heiner-Fokkema, M. R., Green, R. et al. Relationship between serum B12 concentrations and mortality: experience in NHANES. BMC Med 18, 307 (2020). doi.org/10.1186/s12916-020-01771-y. |
| [15] | Mao X, Han L. The Relationship of Methylenetetrahydrofolate Reductase Gene C677T Polymorphism and Ischemic Stroke in Chinese Han Population. Ann Clin Lab Sci. 2018; 48 (2): 242-247. |
| [16] | Wang L, Shen J, Chen CX, et al. The association between homocysteine and the different ischemic stroke subtypes: a meta-analysis. Chin J Gerontol 2018; 38: 2052–5. |
| [17] | Piao X, Wu G, Yang P, Shen J, De A, Wu J, Qu Q. Association between Homocysteine and Cerebral Small Vessel Disease: A Meta-Analysis. J Stroke Cerebrovasc Dis. 2018, 27 (9): 2423-2430. doi: 10.1016/j.jstrokecerebrovasdis.2018.04.035. |
| [18] | Liming Cao, Yi Guo, Zhishan Zhu. Effects of hyperhomocysteinemia on ischemic cerebral small vessel disease and analysis of inflammatory mechanisms. Int J Neurosci. 2020; 1; 1-8. doi: 10.1080/00207454.2020.1744597. |
| [19] | Anniwaer J, Liu MZ, Xue KD, Maimaiti A, Xiamixiding A. Homocysteine might increase the risk of recurrence in patients presenting with primary cerebral infarction. Int J Neurosci. 2019. 129: 654-659. |
| [20] | Yoo JS, Ryu CH, Kim YS, Kim HJ, Bushnell CD, Kim HY. Homocysteinemia is Associated with the Presence of Microbleeds in Cognitively Impaired Patients. J Stroke Cerebrovasc Dis. 2020. 29 (12): 105302. doi: 10.1016/j.jstrokecerebrovasdis.2020.105302. |
| [21] | Huang LQ, Wu CX, Wei HQ, Xu G. Clinical characteristics of H-type hypertension and its relationship with the MTHFR C677T polymorphism in a Zhuang population from Guangxi, China. J Clin Lab Anal. 2020; 34 (11): e23499. doi: 10.1002/jcla.23499. |
| [22] | Tamura T, Kuriyama N, Koyama T, et al. Association between plasma levels of homocysteine, folate, and vitamin B12, and dietary folate intake and hypertension in a cross-sectional study. Sci Rep. 2020; 10 (1): 18499. doi: 10.1038/s41598-020-75267-3. |
| [23] | Khan U, Crossley C, Kalra L, Rudd A, Wolfe CD, Collinson P, et al. Homocysteine and its relationship to stroke subtypes in a UK black population: the south London ethnicity and stroke study. Stroke. 2008. 39: 2943–2949. |
| [24] | Sagui E. Accidenst vasculaires cerebraux en Afrique subsaharienne. Med Trop 2007. 67: 596-600. |
| [25] | Carnethon MR, Pu J, Howard G, Albert MA, Anderson CAM, Bertoni AG et al. Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association. Circulation. 2017, 136: e393-e423. |
APA Style
Damelan Kombate, Sirui Zhou, Panabalo Waklatsi, David Ksc Ahanogbe, Komi Assogba, et al. (2021). MTHFRC677T Polymorphism and Hyperhomocysteinemia in Ischemic Stroke Patients. Clinical Neurology and Neuroscience, 5(3), 55-59. https://doi.org/10.11648/j.cnn.20210503.14
ACS Style
Damelan Kombate; Sirui Zhou; Panabalo Waklatsi; David Ksc Ahanogbe; Komi Assogba, et al. MTHFRC677T Polymorphism and Hyperhomocysteinemia in Ischemic Stroke Patients. Clin. Neurol. Neurosci. 2021, 5(3), 55-59. doi: 10.11648/j.cnn.20210503.14
AMA Style
Damelan Kombate, Sirui Zhou, Panabalo Waklatsi, David Ksc Ahanogbe, Komi Assogba, et al. MTHFRC677T Polymorphism and Hyperhomocysteinemia in Ischemic Stroke Patients. Clin Neurol Neurosci. 2021;5(3):55-59. doi: 10.11648/j.cnn.20210503.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.cnn.20210503.14,
author = {Damelan Kombate and Sirui Zhou and Panabalo Waklatsi and David Ksc Ahanogbe and Komi Assogba and Emile Kou’santa Amouzou and Agnon Ayélola Koffi Balogou and Guy Armand Rouleau},
title = {MTHFRC677T Polymorphism and Hyperhomocysteinemia in Ischemic Stroke Patients},
journal = {Clinical Neurology and Neuroscience},
volume = {5},
number = {3},
pages = {55-59},
doi = {10.11648/j.cnn.20210503.14},
url = {https://doi.org/10.11648/j.cnn.20210503.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cnn.20210503.14},
abstract = {Background: Homocysteine is an intermediate sulfur amino acid of methionine metabolism. Hyperhomocysteinemia, characterized by increased level of homocysteine, is an independent and modifiable vascular risk factor which metabolic pathway involves vitamins B6, folate and vitamin B12. Objective: We compared the prevalence of MTHFRC677T polymorphism, homocysteine folate and vitamin B12 in ischemic stroke patient’s subgroups. Methods: We conducted a cross-sectional analytical study. The study included 128 consecutive ischemic stroke patients associated with hyperhomocysteinemia. The MTHFRC677T polymorphism was investigated by TaqMan probes (thermos Fisher Scientific) combined with polymerase chain reaction (PCR). We compared the prevalence of MTHFRC677T polymorphism and homocysteine level in ischemic stroke patient’s subgroups. We adjusted the variable homocysteine level to the covariates, MTHFR polymorphism, folate and vitamin B12 with ANCOVA. Results: The sex ratio (men/women) was 1.5 with an average age of 60 years. The prevalence of MTHFRC677T polymorphism was 19.5% with 18% CT and 1.5% TT. Homocysteine level was 29.89 µmol/l in wildtype patients, 26.54 µmol/l in patients with CT genotype, and 56.17 µmol/l in patients with TT genotype (t=2.04, p=0.033, CI 95% [0.017; 0.407]). The MTHFR polymorphism prevalence, homocysteine, folate and vitamin B12 level did not differ between large brain infarction and multiple small brain infarction patients respectively (chi square: Qobs=0.05, p=0.94, 95% CI; ttest: t=0.716, df=126, p=0.475, 95% CI). Conclusion: The MTHFRT677T genotype increases homocysteine level. MTHFR polymorphism and homocysteine did not influence the subtypes of brain ischemic stroke.},
year = {2021}
}
TY - JOUR T1 - MTHFRC677T Polymorphism and Hyperhomocysteinemia in Ischemic Stroke Patients AU - Damelan Kombate AU - Sirui Zhou AU - Panabalo Waklatsi AU - David Ksc Ahanogbe AU - Komi Assogba AU - Emile Kou’santa Amouzou AU - Agnon Ayélola Koffi Balogou AU - Guy Armand Rouleau Y1 - 2021/08/18 PY - 2021 N1 - https://doi.org/10.11648/j.cnn.20210503.14 DO - 10.11648/j.cnn.20210503.14 T2 - Clinical Neurology and Neuroscience JF - Clinical Neurology and Neuroscience JO - Clinical Neurology and Neuroscience SP - 55 EP - 59 PB - Science Publishing Group SN - 2578-8930 UR - https://doi.org/10.11648/j.cnn.20210503.14 AB - Background: Homocysteine is an intermediate sulfur amino acid of methionine metabolism. Hyperhomocysteinemia, characterized by increased level of homocysteine, is an independent and modifiable vascular risk factor which metabolic pathway involves vitamins B6, folate and vitamin B12. Objective: We compared the prevalence of MTHFRC677T polymorphism, homocysteine folate and vitamin B12 in ischemic stroke patient’s subgroups. Methods: We conducted a cross-sectional analytical study. The study included 128 consecutive ischemic stroke patients associated with hyperhomocysteinemia. The MTHFRC677T polymorphism was investigated by TaqMan probes (thermos Fisher Scientific) combined with polymerase chain reaction (PCR). We compared the prevalence of MTHFRC677T polymorphism and homocysteine level in ischemic stroke patient’s subgroups. We adjusted the variable homocysteine level to the covariates, MTHFR polymorphism, folate and vitamin B12 with ANCOVA. Results: The sex ratio (men/women) was 1.5 with an average age of 60 years. The prevalence of MTHFRC677T polymorphism was 19.5% with 18% CT and 1.5% TT. Homocysteine level was 29.89 µmol/l in wildtype patients, 26.54 µmol/l in patients with CT genotype, and 56.17 µmol/l in patients with TT genotype (t=2.04, p=0.033, CI 95% [0.017; 0.407]). The MTHFR polymorphism prevalence, homocysteine, folate and vitamin B12 level did not differ between large brain infarction and multiple small brain infarction patients respectively (chi square: Qobs=0.05, p=0.94, 95% CI; ttest: t=0.716, df=126, p=0.475, 95% CI). Conclusion: The MTHFRT677T genotype increases homocysteine level. MTHFR polymorphism and homocysteine did not influence the subtypes of brain ischemic stroke. VL - 5 IS - 3 ER -
Email: